45 completed, 9 recruiting, 6 terminated, 6 unknown. 20 Phase 1, 14 Not applicable, 13 Phase 4, 7 Phase 2, 5 Phase 3.
Follow Iohexol: new trials by email Literature Review of Iohexol trials Research Report on Iohexol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluorescent Probe for Assessment of Renal Elimination Relmapirazin, Iohexol, Medibeacon tGFR monitor - Augmented Renal Clearance, Critical Illness | Phase 4 | Recruiting | Aaron Cook | 200 | 2026-09-01 | 2026-10-07 |
| MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (tGFR), Iohexol - Glomerular Filtration Rate, Heart Failure | Not applicable | Recruiting | MediBeacon | 15 | 2026-08-10 | 2026-08-14 |
| A Study of LY4515100 in Healthy Participants LY4515100 via SAD, LY4515100 via MAD, LY4515100 - Healthy | Phase 1 | Recruiting | Eli Lilly and Company | 123 | 2026-01-15 | 2026-07-29 |
| Contrast and Anesthetic Level With Lumbar Erector Spinae Plan (ESP) Block Ropivacaine (Epidural analgesia), Dexmedetomidine, Iohexol - Pain | Not applicable | Recruiting | University Hospitals Cleveland Medical Center | 32 | 2025-09-15 | 2026-03-11 |
| Low-acid Contrast Media for Preventing Post ERCP Pancreatitis Ioversol, Iopromide, Iohexol - Post-ERCP Acute Pancreatitis | Completed | Shandong University | 3979 | 2025-08-01 | 2026-02-06 | |
| Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy oral iohexol, Lymphangiography and Embolization - Chylous Ascites, Abdominal Neoplasm | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 42 | 2025-02-15 | 2026-03-06 |
| Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) Iohexol - Bacterial Infection | Phase 4 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 161 | 2025-02-12 | 2026-07-31 |
| Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate Iohexol, 125I-iothalamate and 131I-hippuran - Kidney Function Issue, Diagnosis | Not applicable | Unknown | University Medical Center Groningen | 208 | 2024-06-01 | 2024-03-13 |
| Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance Iohexol, pharmacokinetics - Kidney Function Test | Phase 1 | Unknown | Centre Hospitalier Universitaire de Saint Etienne | 48 | 2024-06-01 | 2024-04-29 |
| Chest CT Using Low-concentration Iodine Contrast Media Iohexol (320mgI/mL) with 120kVp, Iohexol (320mgI/mL) with 100kVp, Iohexol (270mgI/mL) with 100kVp - Pulmonary Disease | Phase 4 | Unknown | Jung Im Jung | 370 | 2023-11-24 | 2024-07-25 |
| CT TAVR Abdomen Study Iodinated Contrast Agent (Omnipaque), Dual Energy CT - Transcatheter Aortic Valve Replacement | Phase 4 | Recruiting | University of Maryland, Baltimore | 164 | 2023-09-19 | 2026-07-01 |
| Investigations Into Sepsis-associated Acute Kidney Injury Para Aminohippurate - Acute Kidney Injury | Recruiting | University Hospital of North Norway | 20 | 2023-08-14 | 2025-03-21 | |
| Ultrasound-guided LMBB by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method Lumbar medial branch block, Lidocain, Methylprednisolone - Chronic Low-back Pain, Lumbar Facet Joint Syndrome | Not applicable | Unknown | Erasme University Hospital | 40 | 2023-04-21 | 2023-07-05 |
| Comparison of CE-DBT and MRI in Patients With Known Breast Lesions Iohexol 350 Mg/mL Injectable Solution - Breast Cancer | Early Phase 1 | Terminated | UNC Lineberger Comprehensive Cancer Center | 4 | 2023-03-13 | 2026-07-27 |
| Serum Thyroid Function After Iodinated Contrast Administration Iodinated contrast agents - Thyroid Dysfunction | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 400 | 2023-02-15 | 2023-05-30 | |
| A Study of Effect of LY3556050 on Metformin in Healthy Participants LY3556050, Metformin, Iohexol - Healthy | Phase 1 | Completed | Eli Lilly and Company | 18 | 2022-11-15 | 2023-01-18 |
| A Study of LY3526318 in Healthy Male Japanese Participants LY3526318, Placebo, Iohexol - Healthy | Phase 1 | Withdrawn | Eli Lilly and Company | 2022-11-01 | 2026-09-08 | |
| Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40 - Type 2 Diabetes, Diabetes Type 2 | Completed | University of Colorado, Denver | 57 | 2022-09-30 | 2026-08-24 | |
| MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution - Type 1 Diabetes, Diabetic Kidney Disease | Phase 1 | Recruiting | Kalie Tommerdahl | 60 | 2022-07-01 | 2025-06-13 |
| Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study) Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF), Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR) - Type 1 Diabetes, Diabetic Kidney Disease | Active not recruiting | University of Colorado, Denver | 100 | 2022-03-09 | 2026-05-22 |
Showing 20 of 75. Sign in to see all of them.
Diabetic Nephropathies (7) · Kidney Diseases (6) · Acute Kidney Injury (5) · Diabetes Complications (4) · Diabetes Mellitus, Type 1 (4) · Diabetes Mellitus, Type 2 (4) · Pediatric Obesity (4) · Renal Insufficiency (4) · Heart Failure (3) · Obesity (3) · Breast Neoplasms (2) · Cardiovascular Diseases (2) · Critical Illness (2) · Diabetes Mellitus (2) · Pain (2)
University of Colorado, Denver (8) · Eli Lilly and Company (6) · Centre Hospitalier Universitaire de Saint Etienne (2) · MediBeacon (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Stanford University (2) · Aaron Cook (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Cedars-Sinai Medical Center (1) · Centro Cardiológico del Caribe, Columbia (1) · Columbia University (1) · CyDex Pharmaceuticals, Inc. (1)
United States (48) · France (7) · Canada (4) · Netherlands (4) · United Kingdom (4) · Belgium (3) · China (3) · Norway (2) · Spain (2) · Argentina (1) · Austria (1) · Brazil (1) · Colombia (1) · Finland (1) · Hungary (1)
Petter Bjornstad, MD (5) · Keith Marschke, PhD (2) · Richard B Dorshow, PhD (2) · Aaron M Cook, PharmD (1) · Amy Walz, MD (1) · Andreu Costa, Md FRCPC (1) · Andrew Kepner, MD (1) · Aya Kamaya (1) · Benjamin G Chousterman, MD PhD (1) · Benjamin Yeh, MD (1) · Billy W Loo, Jr, MD, PhD (1) · Celin Malkun, MD, MSc (1)
PMID 32737116, PMID 35507146, PMID 38621633, PMID 12172251, PMID 15182211, PMID 15224630, PMID 15564850, PMID 16274802, PMID 16360518, PMID 16500451, PMID 21564530, PMID 22586008, PMID 22633722, PMID 23137211, PMID 24011252, PMID 25136843, PMID 25293374, PMID 26463883, PMID 27166722, PMID 31439467, PMID 33710029, PMID 36623423, PMID 39368039, PMID 39436695, PMID 39918882, PMID 40126554, PMID 40178463, PMID 41708511, PMID 42028604
2014 (2), 5UM1AI104681-12 (1), K08CA252457 (1), K23HL159292 (1), U10CA180868 (1), UL1TR001082 (1)